DGNS Stock Overview
Provides health services using laboratories in Indonesia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
PT Diagnos Laboratorium Utama Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp198.00 |
| 52 Week High | Rp436.00 |
| 52 Week Low | Rp188.00 |
| Beta | 0.50 |
| 1 Month Change | -13.16% |
| 3 Month Change | -34.87% |
| 1 Year Change | -26.12% |
| 3 Year Change | -73.95% |
| 5 Year Change | n/a |
| Change since IPO | -26.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| DGNS | ID Healthcare | ID Market | |
|---|---|---|---|
| 7D | -6.6% | -2.4% | -3.6% |
| 1Y | -26.1% | 17.4% | 2.7% |
Return vs Industry: DGNS underperformed the ID Healthcare industry which returned 17.3% over the past year.
Return vs Market: DGNS underperformed the ID Market which returned 2.7% over the past year.
Price Volatility
| DGNS volatility | |
|---|---|
| DGNS Average Weekly Movement | 8.3% |
| Healthcare Industry Average Movement | 5.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in ID Market | 12.8% |
| 10% least volatile stocks in ID Market | 2.4% |
Stable Share Price: DGNS has not had significant price volatility in the past 3 months compared to the ID market.
Volatility Over Time: DGNS's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 91 | Mesha Sini | diagnos.co.id |
PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers clinical pathology laboratory tests comprising hematology, hemostasis, clinical chemistry, urinalysis, biomolecular, immunology, microbiology, and anatomical pathology; and genomics laboratory tests that provides genetic testing for reproductive health, pregnant women, couples who want to have a child, oncology tests, drug sensitivity, DNAandMe, and others. It also offers homecare health services for hemoglobin, ferritin, retilulosit, hematologi rutin, SARS-COV-2 omicron screening molecular test, and PCR SARS-COV-2 H+1 B2C; and SARS-CoV-2 screening services.
PT Diagnos Laboratorium Utama Tbk Fundamentals Summary
| DGNS fundamental statistics | |
|---|---|
| Market cap | Rp247.50b |
| Earnings (TTM) | -Rp4.76b |
| Revenue (TTM) | Rp155.53b |
1.6x
P/S Ratio-52.0x
P/E RatioIs DGNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DGNS income statement (TTM) | |
|---|---|
| Revenue | Rp155.53b |
| Cost of Revenue | Rp88.78b |
| Gross Profit | Rp66.75b |
| Other Expenses | Rp71.51b |
| Earnings | -Rp4.76b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.81 |
| Gross Margin | 42.92% |
| Net Profit Margin | -3.06% |
| Debt/Equity Ratio | 17.8% |
How did DGNS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:32 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PT Diagnos Laboratorium Utama Tbk is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|